A low-cost, paper-based hybrid capture assay to detect high-risk HPV DNA for cervical cancer screening in low-resource settings

Smith, Chelsey; Chang, Megan; Kundrod, Kathryn; Newsham, Emilie I; Parra, Sonia; López, Leticia; Mavume, Celda; Lorenzoni, Cesaltina; Maza, Mauricio; Salcedo, Mila Pontremoli; Carns, Jennifer; Baker, Ellen; Montealegre, Jane R.; Scheurer, Michael E.; Castle, Philip E.; Schmeler, Kathleen M.; Richards‐Kortum, Rebecca

doi:10.1039/d2lc00885h

Cited by 13 publications

(9 citation statements)

References 41 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…158 Images of droplets to confirm presence of amplified HPV products recently reported by Richards-Kortum group. 161 The assay comprised two-dimensional paper network (2DPN) and a point-of-care sample preparation protocol to detect HPV16 DNA from exfoliated cervical cells within an hour. It was conducted not only in controlled laboratory settings using cervical samples from Salvador but also in field settings in Mozambique on self-collected samples.…”

Section: Microfluidics and Lab-on-a-chip Technology-integrating Indiv...mentioning

confidence: 99%

“…Another significant drawback is that most of these technologies were not yet fully tested in low‐resource settings outside well‐equipped laboratories or hospitals. Only few relevant studies, mostly utilizing LFA combined with RPA 98 or paperfludic device with hybrid capture technology, 161 showed performance in low‐resource settings in developing countries. Authors of the former study even estimated a cost of a single test to be around $5, a very affordable price due to their extraction‐free and PCR‐free approach 98 .…”

Section: Conclusion and Recommendationsmentioning

confidence: 99%

“…Importantly, all reactions and washing steps are performed in sealed reaction systems, ideal for preventing cross‐contamination. LOC technology represents rapidly growing field in DNA diagnostics, and numerous devices were introduced also for HPV analysis 153–167 …”

Section: Microfluidics and Lab‐on‐a‐chip Technology—integrating Indiv...mentioning

confidence: 99%

“…LOC technology represents rapidly growing field in DNA diagnostics, and numerous devices were introduced also for HPV analysis. [153][154][155][156][157][158][159][160][161][162][163][164][165][166][167] For example, an interesting innovation was an automated diagnostics of high-risk HPVs by using machine learning coupled with single-cell droplet PCR and multiplexed microfluidics chip. 158 Images of droplets to confirm presence of amplified HPV products recently reported by Richards-Kortum group.…”

Section: Microfluidics and Lab-on-a-chip Technology-integrating Indiv...mentioning

confidence: 99%

“…Although two out of five negative samples exhibited faint positive test lines, most probably due to self‐priming of LAMP primers, this low‐cost disposable paperfludic chip could represent a viable option for quick diagnostics of HPV infection once the issue of false positives is resolved. A combination of above‐mentioned principles, that is, hybrid capture strategy to avoid DNA amplification and paper‐based assay without a need for pumps, has been very recently reported by Richards‐Kortum group 161 . The assay comprised two‐dimensional paper network (2DPN) and a point‐of‐care sample preparation protocol to detect HPV16 DNA from exfoliated cervical cells within an hour.…”

Section: Microfluidics and Lab‐on‐a‐chip Technology—integrating Indiv...mentioning

confidence: 99%

See 4 more Smart Citations

Advanced technologies towards improved HPV diagnostics

Bartosik,

Moranova,

Izadi

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Persistent infection with high‐risk types of human papillomaviruses (HPV) is a major cause of cervical cancer, and an important factor in other malignancies, for example, head and neck cancer. Despite recent progress in screening and vaccination, the incidence and mortality are still relatively high, especially in low‐income countries. The mortality and financial burden associated with the treatment could be decreased if a simple, rapid, and inexpensive technology for HPV testing becomes available, targeting individuals for further monitoring with increased risk of developing cancer. Commercial HPV tests available in the market are often relatively expensive, time‐consuming, and require sophisticated instrumentation, which limits their more widespread utilization. To address these challenges, novel technologies are being implemented also for HPV diagnostics that include for example, isothermal amplification techniques, lateral flow assays, CRISPR‐Cas‐based systems, as well as microfluidics, paperfluidics and lab‐on‐a‐chip devices, ideal for point‐of‐care testing in decentralized settings. In this review, we first evaluate current commercial HPV tests, followed by a description of advanced technologies, explanation of their principles, critical evaluation of their strengths and weaknesses, and suggestions for their possible implementation into medical diagnostics.

show abstract

Section: Microfluidics and Lab-on-a-chip Technology-integrating Indiv...mentioning

confidence: 99%

Section: Conclusion and Recommendationsmentioning

confidence: 99%

Section: Microfluidics and Lab‐on‐a‐chip Technology—integrating Indiv...mentioning

confidence: 99%

Section: Microfluidics and Lab-on-a-chip Technology-integrating Indiv...mentioning

confidence: 99%

Section: Microfluidics and Lab‐on‐a‐chip Technology—integrating Indiv...mentioning

confidence: 99%

See 3 more Smart Citations

Advanced technologies towards improved HPV diagnostics

Bartosik,

Moranova,

Izadi

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

An Injection Molded SlipChip with Self‐Sampling for Integrated Point‐of‐Care Testing of Human Papilloma Virus

Zhang,

Dong,

et al. 2024

Advanced Science

View full text Add to dashboard Cite

High‐risk human papillomavirus (HPV) screening is crucial for cervical cancer prevention. However, laboratory‐based nucleic acid amplification tests (NAATs) require costly equipment, designated lab space, and skilled personnel. Additionally, cervical swabs collected by healthcare professionals can be inconvenient, uncomfortable, and reduce privacy, limiting broader application and patient compliance. A SlipChip‐based Integrated Point‐of‐Care (SIPOC) system featuring an injection‐molded SlipChip is presented with preloaded reagents for nucleic acid extraction and a portable four‐channel real‐time quantitative PCR instrument for detection. This system incorporates a self‐sampling method that allows participants to collect their own vaginal swabs, with the β‐Globin gene as a control. After testing 130 participants for HPV‐16 and HPV‐18, 97.7% of the self‐collected samples are valid. Among valid samples, 25 tested positive for HPV‐16 and 9 for HPV‐18. Compared to Roche's standard HPV PCR test, the SIPOC system shows 100% positive predictive value (PPV) for both HPV‐16 and HPV‐18 and negative predictive values (NPVs) of 99.0% and 99.1%, respectively. This system is promising for HPV screening in resource‐limited settings and adaptable for other point‐of‐care NAAT applications, including home testing.

show abstract

Evaluation of Applied Artificial Neuronal Networks with a Timely Cervical Cancer Diagnosis in an Emerging Economy

Mota-López,

Barojas-Payán,

Hernández-Cisneros

et al. 2024

Management and Industrial Engineering

View full text Add to dashboard Cite

A low-cost, paper-based hybrid capture assay to detect high-risk HPV DNA for cervical cancer screening in low-resource settings

Abstract: Cervical cancer is a leading cause of cancer death for women in low-resource settings. The World Health Organization recommends that cervical cancer screening programs incorporate HPV DNA testing, but available...

Cited by 13 publications

References 41 publications

Advanced technologies towards improved HPV diagnostics

Advanced technologies towards improved HPV diagnostics

An Injection Molded SlipChip with Self‐Sampling for Integrated Point‐of‐Care Testing of Human Papilloma Virus

Evaluation of Applied Artificial Neuronal Networks with a Timely Cervical Cancer Diagnosis in an Emerging Economy

Contact Info

Product

Resources

About